BBBrian Bolwell

Brian Bolwell

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Brian Bolwell has a total of 31 co-authors. Here are the top co-authors by number of shared publications:

  • B Pohlman

    Department of Hematology and Medical Oncology, Bone Morrow Trasplant Program, Taussig Cancer Center, The Cleveland Clinic Foundation, Cleveland, OH, USA

    3 shared publications
  • L Rybicki

    Department of Biostatistics and Epidemiology, Taussig Cancer Center, The Cleveland Clinic Foundation, Cleveland, OH, USA

    3 shared publications
  • M Kalaycio

    Department of Hematology and Medical Oncology, Bone Morrow Trasplant Program, Taussig Cancer Center, The Cleveland Clinic Foundation, Cleveland, OH, USA

    3 shared publications
  • R Sobecks

    Department of Hematology and Medical Oncology, Bone Morrow Trasplant Program, Taussig Cancer Center, The Cleveland Clinic Foundation, Cleveland, OH, USA

    3 shared publications
  • S Andresen

    Department of Hematology and Medical Oncology, Bone Morrow Trasplant Program, Taussig Cancer Center, The Cleveland Clinic Foundation, Cleveland, OH, USA

    3 shared publications
  • E Kuczkowski

    Department of Hematology and Medical Oncology, Bone Morrow Trasplant Program, Taussig Cancer Center, The Cleveland Clinic Foundation, Cleveland, OH, USA

    2 shared publications

Latest Publications

  • Severe mucositis is associated with reduced survival after autologous stem cell transplantation for lymphoid malignancies

    by S. R. Fanning, L. Rybicki, M. Kalaycio, S. Andresen, E. Kuczkowski, B. Pohlman, R. Sobecks, J. Sweetenham, B. Bolwell

    Summary: Mucositis is a known complication of autologous stem cell transplantation (ASCT). This study retrospectively reviewed 191 patients with lymphoid malignancies undergoing ASCT following a uniform mobilising regimen of etoposide (VP‐16)/granulocyte colony‐stimulating factor and a uniform high‐dose preparative regimen of busulfan/cyclophosphamide/VP‐16. Eighty‐seven patients experienced severe mucositis (modified Oral Mucositis Assessment Scale ≥1). Patient characteristics compared between mucositis groups were balanced according to disease status, prior exposure to radiation therapy, time from radiation therapy and actual body weight. Log‐rank analysis revealed that severe mucositis was associated with inferior overall survival (P = 0·002). A 12‐month landmark analysis showed this difference in survival occurred within 1 year post‐transplant. Multivariate analysis of all‐cause mortality showed lower pretransplant albumin and severe mucositis to be significant risk factors. Multivariate analysis for relapse mortality revealed severe mucositis to be a risk factor (P = 0·047), while lower pretransplant albumin was significant for non‐relapse mortality (NRM; P = 0·009). Kaplan–Meier estimates of survival based on relapse and NRM were significantly worse for patients with severe mucositis. Reduced pretransplant forced expiratory volume in 1 s (FEV1) and carbon monoxide (CO) diffusing capacity (DLCO) were also associated with severe mucositis. Our data suggest that studies of new treatment strategies for mucositis should include relapse and survival endpoints and that pretransplant factors, such as FEV1 and DLCO may be useful to risk‐stratify patients entered onto such trials.


  • Factors predicting success or failure associated with common types of transplants

    by Brian J. Bolwell

    The ability to predict clinical outcomes is essential to accurate medical decision analysis. Many accepted bone marrow transplant related prognostic variables are derived from data that is over 20-years old and may or may not be applicable to current medical practice. This report reviews both older data concerning bone marrow transplantation prognostic factors as well as more current reports. In addition to pretransplant variables, this review examines easily measured post-transplant variables that may affect prognosis, as well as data concerning the cellular component of the infused graft in both allogeneic and autologous transplantation.


  • Open Access

    Dendritic cells in autologous hematopoietic stem cell transplantation for diffuse large B-cell lymphoma: graft content and post transplant recovery predict survival

    by R Dean, P Masci, B Pohlman, S Andresen, S Serafino, R Sobecks, E Kuczkowski, J Curtis, J Maciejewski, L Rybicki, et al.

    Allograft dendritic cell (DC) content has been identified as a predictor of relapse and event-free survival after allogeneic bone marrow transplantation. However, the prognostic importance of DCs has not been evaluated in the setting of autologous hematopoietic stem cell transplantation (HSCT). We prospectively determined pre-transplant and post transplant DC levels, including DC1 and DC2 subset levels, in 53 patients with diffuse large B-cell non-Hodgkin's lymphoma (DLBC NHL) undergoing autologous HSCT. Pre-transplant DCs were measured in the collected stem cell products and were therefore indicative of cell numbers infused directly into patients; post transplant analysis of DCs was performed on the peripheral blood of patients 6 weeks after the infusion of autologous stem cells. Higher pre-transplant levels of DC1 cells and total DCs were significantly associated with improved survival. Similarly, greater post transplant levels of total DCs and both subsets were significantly associated with survival. These findings suggest a relationship between DC reconstitution and survival following autologous HSCT for DLBC NHL. Strategies to increase autograft DC content or accelerate DC recovery after autologous HSCT might improve outcomes in this setting.


  • A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation

    by B Bolwell, R Sobecks, B Pohlman, S Andresen, L Rybicki, E Kuczkowski, M Kalaycio

    Cyclosporine (CSP) and short course methotrexate (MTX) have been the gold standard for GVHD prophylaxis for decades. Problems associated with MTX include increased time to hematopoietic engraftment, mucositis, and other organ toxicities. The combination of CSP with mycophenolate mofetil (MMF) has been used successfully for the prevention of graft rejection and GVHD in nonmyeloablative transplantation. We performed a prospective randomized trial comparing CSP and MTX with CSP and MMF in myeloablative (busulfan based) allogeneic 6/6 matched sibling bone marrow transplantation (BMT). The group receiving MMF (n=21) had significantly less severe mucositis than did the group receiving MTX (n=19) (21 vs 65%, P=0.008). Median time to neutrophil engraftment was more rapid in the MMF group (11 vs 18 days, P<0.001). The incidence of acute GVHD, as well as 100 day survival, was similar for both groups. The reduced toxicity of the CSP and MMF arm resulted in premature study closure. We conclude that a GVHD prophylaxis regimen of CSP and MMF after a myeloablative allogeneic preparative regimen is associated with faster hematopoietic engraftment, decreased incidence of mucositis, similar incidence of aGVHD, and comparable survival as compared to CSP and MTX.


  • Prognostic importance of the platelet count 100 days post allogeneic bone marrow transplant

    by B Bolwell, B Pohlman, R Sobecks, S Andresen, S Brown, L Rybicki, V Wentling, M Kalaycio

    We assessed the prognostic importance of the platelet count 100 days post transplant of 107 consecutive patients receiving ablative allogeneic bone marrow transplant (BMT) between 7/96 and 12/00 who survived at least 100 days. Diagnoses included AML (n=36), chronic myelogenous leukemia (n=27), NHL (n=14), ALL (n=16), MDS (n=9), aplastic anemia (n=3), and one Hodgkin's disease and myelofibrosis each. In total, 64% were in remission or in chronic phase or had aplastic anemia (good risk), and 36% had active disease at the time of transplant (bad risk). In all, 70% were matched sibling transplants and 30% were matched unrelated donor transplants. The mean follow-up for the patients remaining alive is 48 months. Survival was powerfully influenced by the 100-day platelet count: 4-year survival was 19% for patients with a platelet count 9/l; 41% for patients with a platelet count of 30–50; and 72% for those with a platelet count >50 (PPP=0.009). We conclude that the platelet count 100 days post transplant is a powerful predictor of overall survival.


  • Autologous Peripheral Blood Progenitor Cell Transplantation for Transformed Diffuse Large-Cell Lymphoma

    by Brian Bolwell, Matt Kalaycio, Steven Andresen, Marlene Goormastic, Melissa McBee, Elizabeth Kuczkowski, Kimberly Wise, Ronald Sobecks, Brad Pohlman